Pharming Group (PHAR)
(Delayed Data from NSDQ)
$10.96 USD
-0.15 (-1.35%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $11.08 +0.12 (1.09%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PHAR 10.96 -0.15(-1.35%)
Will PHAR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PHAR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PHAR
New Strong Buy Stocks for August 1st
Best Momentum Stocks to Buy for July 25th
PHAR: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for July 25th
Best Momentum Stocks to Buy for July 17th
New Strong Buy Stocks for July 17th
Other News for PHAR
Pharming (PHAR) Stock Target Raised by Oppenheimer Following Q2 Results
Pharming price target raised by $1 at Oppenheimer, here's why
Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript
Pharming Group N.V. 2025 Q2 - Results - Earnings Call Presentation
Pharming Group N.V. GAAP EPS of $0.006, revenue of $93.2M